Cubist Beats, Ups View
Cubist Pharmaceuticals, Inc.’s (NASDAQ:CBST) first quarter 2012 earnings (excluding special items but including stock-based compensation expense) came in at 82 cents per share up 51.9% from the year-ago period. Reported earnings came in at 45 cents, up 32.4% year-over-year. The Zacks Consensus Estimate for the first quarter was 41 cents. Results in the quarter were [...]
Cubist Pharmaceuticals, Inc.’s (NASDAQ:CBST) first quarter 2012 earnings (excluding special items but including stock-based compensation expense) came in at 82 cents per share up 51.9% from the year-ago period.
Reported earnings came in at 45 cents, up 32.4% year-over-year. The Zacks Consensus Estimate for the first quarter was 41 cents. Results in the quarter were helped by strong sales of antibiotic injection, Cubicin (daptomycin).
Revenue in the first quarter of 2012 climbed 30.0% to $211.7 … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards